NASDAQ:ACORQ Acorda Therapeutics (ACORQ) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free ACORQ Stock Alerts $0.25 -0.01 (-3.85%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.25▼$0.9052-Week Range$0.23▼$18.21Volume4,280 shsAverage Volume29,603 shsMarket Capitalization$310,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends Get Acorda Therapeutics alerts: Email Address Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Acorda TherapeuticsAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.Read More ACORQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACORQ Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ACORQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACORQ CUSIPN/A CIK1008848 Webwww.acorda.com Phone914-347-4300Fax914-347-4560Employees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($212.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-252,850,000.00 Net Margins-227.75% Pretax Margin-263.21% Return on Equity-2,206.93% Return on Assets-114.39% Debt Debt-to-Equity Ratio3.07 Current Ratio0.22 Quick Ratio0.15 Sales & Book Value Annual Sales$117.63 million Price / Sales0.00 Cash Flow$25.00 per share Price / Cash Flow0.01 Book Value($127.17) per share Price / Book0.00Miscellaneous Outstanding Shares1,242,000Free Float1,210,000Market Cap$310,500.00 OptionableN/A Beta1.63 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $897.4kMr. Michael A. Gesser M.B.A. (Age 61)CFO & Treasurer Comp: $611.55kMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Comp: $616.27kMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kSofia AliSenior VP of Operations & Strategic PlanningSusan WaySenior VP of Drug Development & Regulatory AffairsDr. Wise Young M.D. (Age 74)Ph.D., Special Scientific Advisor Comp: $10kMore ExecutivesKey CompetitorsPeak BioNASDAQ:PKBOIgnyte AcquisitionNASDAQ:IGNYGenocea BiosciencesNASDAQ:GNCAGenocea BiosciencesNASDAQ:GNCAQVectivBioNASDAQ:VECTView All Competitors ACORQ Stock Analysis - Frequently Asked Questions How have ACORQ shares performed in 2024? Acorda Therapeutics' stock was trading at $0.44 at the beginning of the year. Since then, ACORQ shares have decreased by 43.2% and is now trading at $0.25. View the best growth stocks for 2024 here. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACORQ) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($22.06) EPS for the quarter. The business had revenue of $20.29 million for the quarter. Acorda Therapeutics had a negative net margin of 227.75% and a negative trailing twelve-month return on equity of 2,206.93%. How do I buy shares of Acorda Therapeutics? Shares of ACORQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACORQ) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acorda Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.